S2-E37.2 - NASH Diagnostics Provide a Natural Brake on Overly Broad Adoption of NASH Drugs
Send us a text Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. This conversation focuses on the unique challenges posed by the complexity of NASH and NAFLD and the current state of diagnostic testing. It has been common for industry advocates and financial analysts to discuss the potential for the NASH/NAFLD drug market in comparison to the statin market, but this overlooks differences in the condi...
17 Juli 202115min
S2-E37.1 - Key Reasons the NASH Drug Market Will Evolve Differently From Statins
Send us a text Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. In this conversation, each panelist identifies one significant reason the NASH market will develop differently than statins did. It has been common for industry advocates and financial analysts to discuss the potential for the NASH/NAFLD drug market in comparison to the statin market, but this overlooks differences in the conditions the...
17 Juli 202111min
S2-E37 - Why the NASH Market Is Different From Statins
Send us a text Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. It has been common for industry advocates and financial analysts to discuss the potential for the NASH/NAFLD drug market in comparison to the statin market, but this overlooks differences in the conditions they treat (NASH vs. hypercholesterolemia), the diagnostics available and the health economic environment. This episode pinpoints th...
15 Juli 202158min
S2-E36.3 - From the #ILC2021 Wrap-up: Focus on Care Pathways and Treatment Roles
Send us a text Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers issues around care pathways and treatment roles as NASH becomes recognized as a multidisciplinary health challenge. The conversation started with a discussion of the attention paid to multi-disciplinary treatment in the #ILC2021 program and evolved into a look at the roles that primary care and dif...
4 Juli 202111min
S2-E36.2 - From The #ILC2021 Wrap-Up: Focus On Drug Development
Send us a text Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers issues around drug development. The conversation addressed the various ways that the challenges that the COVID-19 pandemic created for clinical trials in 2020 played out in the drug development presentations at #ILC2021: a higher level of retrospective analysis of earlier trials and relatively few ...
3 Juli 202113min
S2-E36.1 - From the #ILC2021 Wrap-up: Focus on Diagnostics
Send us a text Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers issues around diagnostics. The conversation covered several issues relating to use and interpretation of non-invasive testing. Two issues addressed use on NITs in diagnostics and, separately, drug development. A third considered how to develop and support end points generated around non-invasive te...
3 Juli 202116min
S2-E36 - #ILC2021 Wrap-Up: Big Issues, Key Takeaways, Remaining Issues
Send us a text Key opinion leaders Quentin Anstee, Mazen Noureddin and Ian Rowe join Stephen, Louise and Roger to discuss the major lessons and dangling questions from #ILC2021. The group shares perspectives, insights and questions on four key topics: diagnostics (including both non-invasive technologies and AI/machine learning), drug development, patient populations and policy.Mixed in here you will find discussions on food insecurity, polygenic risk and multi-disciplinary medicine. A great ...
1 Juli 202157min
S2-E35 - #ILC2021 Day Four - Promising Times Ahead, Maybe With a Few More Bumps In the Road
Send us a text Donna Cryer, Vlad Ratziu, Michael Charlton and Mazen Noureddin join Roger Green in reviewing the final day of #ILC 2021. The conversation revolved around three themes: non-invasive tests as presented at the morning LITMUS session; two promising but incomplete drug trials for a new class of agents and a possible therapy for controlled cirrhotics, and the opportunities and challenges presented by digital meetings (with kudos to EASL for all the platform elements they strengthened...
26 Juni 20211h 13min
